Literature DB >> 19003546

Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer.

Hui-chan He1, Xue-cheng Bi, Zhi-wei Zheng, Qi-shan Dai, Zhao-Dong Han, Yu-Xiang Liang, Yong-Kang Ye, Guo-hua Zeng, Gang Zhu, Wei-de Zhong.   

Abstract

To investigate the expressions of PIM-1 and hK2 mRNA in normal prostate, benign prostatic glandular hyperplasia (BPH), and prostate cancer (PCa), and to explore the association of PIM-1 and hK2 expressions with PCa progression. The samples were harvested from 37 patients with BPH, 23 patients with PCa, and three with normal prostate tissues. Total RNA was extracted from their prostate tissues and analyzed for PIM-1 and hK2 mRNA levels using SYBR green I-based quantitative real-time RT-PCR (QRT-PCR) assays and Southern blot analysis. The differences of gene expressions were calculated based on standard curve. Quantitative expressions of PIM-1 and hK2 mRNA in normal prostate, BPH, and PCa were 1.05 +/- 0.04, 2.57 +/- 0.74, 4.45 +/- 0.63, and 1.02 +/- 0.03, 2.264 +/- 0.46, 5.905 +/- 0.78, respectively. PIM-1 and hK2 were expressed higher in PCa than those in BPH and normal prostate tissues, the differences among which had statistic significance (P < 0.05). Our results support the hypothesis that PIM-1 and hK2 play a significant role in the growth of PCa and the detection of PIM-1 and hK2 mRNA expressions by QRT-PCR provided more reliable and helpful information on diagnosis, treatment, and prognosis of PCa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19003546     DOI: 10.1007/s12032-008-9120-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

Review 1.  Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.

Authors:  Z Wang; N Bhattacharya; M Weaver; K Petersen; M Meyer; L Gapter; N S Magnuson
Journal:  J Vet Sci       Date:  2001-12       Impact factor: 1.672

Review 2.  PSA updated: still relevant in the new millennium?

Authors:  Jay B Shah; Adam C Reese; James M McKiernan; Mitchell C Benson
Journal:  Eur Urol       Date:  2005-01-12       Impact factor: 20.096

Review 3.  Real-time PCR in clinical microbiology: applications for routine laboratory testing.

Authors:  M J Espy; J R Uhl; L M Sloan; S P Buckwalter; M F Jones; E A Vetter; J D C Yao; N L Wengenack; J E Rosenblatt; F R Cockerill; T F Smith
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Quantification of mRNA using real-time RT-PCR.

Authors:  Tania Nolan; Rebecca E Hands; Stephen A Bustin
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.

Authors:  Shahrokh F Shariat; Emanuel Gottenger; Cuong Nguyen; Weitao Song; Michael W Kattan; John Andenoro; Thomas M Wheeler; David M Spencer; Kevin M Slawin
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

Review 6.  Human tissue kallikrein gene family: applications in cancer.

Authors:  Christina V Obiezu; Eleftherios P Diamandis
Journal:  Cancer Lett       Date:  2005-06-16       Impact factor: 8.679

7.  Development of sensitive immunoassays for free and total human glandular kallikrein 2.

Authors:  Ville Väisänen; Susann Eriksson; Kaisa K Ivaska; Hans Lilja; Martti Nurmi; Kim Pettersson
Journal:  Clin Chem       Date:  2004-07-09       Impact factor: 8.327

8.  Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

Authors:  Ralf Kurek; German Nunez; Nikolaos Tselis; Lutz Konrad; Thomas Martin; Sandra Roeddiger; Gerd Aumüller; Nikolaos Zamboglou; Daniel W Lin; Ulf W Tunn; Heiner Renneberg
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

9.  Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).

Authors:  B J Martin; J A Finlay; K Sterling; M Ward; D Lifsey; D Mercante; J M Jainto; L Martin; W Rayford
Journal:  Prostate Cancer Prostatic Dis       Date:  2004       Impact factor: 5.554

Review 10.  [Prostate cancer and prostate specific antigen screening].

Authors:  M Camici
Journal:  Minerva Med       Date:  2004-02       Impact factor: 4.806

View more
  12 in total

1.  p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.

Authors:  Marina Zemskova; Michael B Lilly; Ying-Wei Lin; Jin H Song; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2010-07-20       Impact factor: 5.852

Review 2.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

Review 3.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 4.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

5.  Androgen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer.

Authors:  Jiang Wang; Gang Li; Bo Li; Hualin Song; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Oncol Lett       Date:  2017-04-07       Impact factor: 2.967

6.  Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.

Authors:  Marina Y Zemskova; Jin H Song; Bo Cen; Javier Cerda-Infante; Viviana P Montecinos; Andrew S Kraft
Journal:  Cell Signal       Date:  2014-10-28       Impact factor: 4.315

7.  Expressions of Osteopontin (OPN), ανβ3 and Pim-1 Associated with Poor Prognosis in Non-small Cell Lung Cancer (NSCLC).

Authors:  Yi Jin; Da-Yue Tong; Lu-Ying Tang; Jian-Ning Chen; Jing Zhou; Zhi-Ying Feng; Chun-Kui Shao
Journal:  Chin J Cancer Res       Date:  2012-06       Impact factor: 5.087

8.  miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Authors:  Omer Faruk Karatas; Jianghua Wang; Longjiang Shao; Mustafa Ozen; Yiqun Zhang; Chad J Creighton; Michael Ittmann
Journal:  Oncotarget       Date:  2017-07-24

9.  Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.

Authors:  Yi Jin; Da-yue Tong; Jian-ning Chen; Zhi-ying Feng; Jian-yong Yang; Chun-kui Shao; Jia-ping Li
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Long Noncoding RNA LINC01410 Suppresses Tumorigenesis and Enhances Radiosensitivity in Neuroblastoma Cells Through Regulating miR-545-3p/HK2 Axis.

Authors:  Liping Mou; Lili Wang; Shaoming Zhang; Qinghua Wang
Journal:  Onco Targets Ther       Date:  2021-05-18       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.